MX2021011007A - Farmaco y método para tratar o prevenir las complicaciones de la diabetes mediante el uso del mismo farmaco. - Google Patents
Farmaco y método para tratar o prevenir las complicaciones de la diabetes mediante el uso del mismo farmaco.Info
- Publication number
- MX2021011007A MX2021011007A MX2021011007A MX2021011007A MX2021011007A MX 2021011007 A MX2021011007 A MX 2021011007A MX 2021011007 A MX2021011007 A MX 2021011007A MX 2021011007 A MX2021011007 A MX 2021011007A MX 2021011007 A MX2021011007 A MX 2021011007A
- Authority
- MX
- Mexico
- Prior art keywords
- drug
- diabetes
- treating
- preventing complications
- complications
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Emergency Medicine (AREA)
- Ophthalmology & Optometry (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Abstract
Un fármaco que contiene un compuesto representado por la fórmula (I) como un ingrediente activo, usado para las complicaciones de la diabetes.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2019044670 | 2019-03-12 | ||
PCT/JP2020/010967 WO2020184691A1 (ja) | 2019-03-12 | 2020-03-12 | 薬剤及び該薬剤を用いて糖尿病合併症を治療又は予防する方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2021011007A true MX2021011007A (es) | 2022-03-11 |
Family
ID=72426033
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2021011007A MX2021011007A (es) | 2019-03-12 | 2020-03-12 | Farmaco y método para tratar o prevenir las complicaciones de la diabetes mediante el uso del mismo farmaco. |
Country Status (15)
Country | Link |
---|---|
US (1) | US20220218664A1 (es) |
EP (1) | EP3939659A4 (es) |
JP (1) | JPWO2020184691A1 (es) |
KR (1) | KR20220009371A (es) |
CN (1) | CN114126711A (es) |
AU (1) | AU2020238177A1 (es) |
BR (1) | BR112021018084A8 (es) |
CA (1) | CA3133204A1 (es) |
CL (1) | CL2021002373A1 (es) |
EA (1) | EA202192483A1 (es) |
IL (1) | IL286289A (es) |
MX (1) | MX2021011007A (es) |
PE (1) | PE20220333A1 (es) |
SG (1) | SG11202109982YA (es) |
WO (1) | WO2020184691A1 (es) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20220040294A (ko) * | 2020-09-23 | 2022-03-30 | 씨엔지바이오 주식회사 | 6-메톡시-2-펜에틸이소인돌린-1-온 유도체 및 이를 포함하는 신경질환의 치료용 조성물 |
CN116669723A (zh) * | 2021-02-10 | 2023-08-29 | 上海森辉医药有限公司 | 一种smtp-7衍生物及其用途 |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH05176782A (ja) * | 1992-01-08 | 1993-07-20 | Taisho Pharmaceut Co Ltd | Ngf作用増強因子 |
JP2004224737A (ja) | 2003-01-23 | 2004-08-12 | Ttc:Kk | 新規トリプレニルフェノール化合物 |
JP4313049B2 (ja) * | 2003-01-23 | 2009-08-12 | 株式会社ティーティーシー | 血管新生関連疾患の予防又は治療用医薬組成物 |
EP1944027A4 (en) | 2005-10-06 | 2009-08-19 | Univ Tokyo Nat Univ Corp | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OR PREVENTION OF NEPHRITIS AND METHOD FOR PRODUCING THE SAME |
US8110596B2 (en) | 2006-03-27 | 2012-02-07 | Tokyo University Of Agriculture And Technology Tlo Co., Ltd. | Triprenyl phenol compound, process for production of triprenyl phenol compound, and thrombolysis enhancer |
WO2010110026A1 (ja) * | 2009-03-25 | 2010-09-30 | 国立大学法人東京農工大学 | メタボリックシンドローム、肥満、高血糖症、高脂血症および/又は脂肪肝のための医薬組成物 |
JP5605659B2 (ja) * | 2009-07-06 | 2014-10-15 | 国立大学法人東京農工大学 | 細胞保護剤 |
WO2011125930A1 (ja) * | 2010-04-02 | 2011-10-13 | 日本製薬株式会社 | 炎症性腸疾患又は自己免疫性の末梢神経障害の予防又は治療剤 |
WO2012115209A1 (ja) * | 2011-02-24 | 2012-08-30 | 国立大学法人東京農工大学 | 可溶性エポキシドハイドロラーゼ阻害剤 |
JP2019044670A (ja) | 2017-08-31 | 2019-03-22 | スズキ株式会社 | 内燃機関の排出ガス浄化システム |
-
2020
- 2020-03-12 JP JP2021505150A patent/JPWO2020184691A1/ja not_active Withdrawn
- 2020-03-12 BR BR112021018084A patent/BR112021018084A8/pt unknown
- 2020-03-12 CN CN202080035808.7A patent/CN114126711A/zh active Pending
- 2020-03-12 MX MX2021011007A patent/MX2021011007A/es unknown
- 2020-03-12 CA CA3133204A patent/CA3133204A1/en active Pending
- 2020-03-12 US US17/438,801 patent/US20220218664A1/en active Pending
- 2020-03-12 SG SG11202109982Y patent/SG11202109982YA/en unknown
- 2020-03-12 PE PE2021001508A patent/PE20220333A1/es unknown
- 2020-03-12 EA EA202192483A patent/EA202192483A1/ru unknown
- 2020-03-12 WO PCT/JP2020/010967 patent/WO2020184691A1/ja unknown
- 2020-03-12 KR KR1020217032312A patent/KR20220009371A/ko unknown
- 2020-03-12 EP EP20771088.0A patent/EP3939659A4/en not_active Withdrawn
- 2020-03-12 AU AU2020238177A patent/AU2020238177A1/en not_active Abandoned
-
2021
- 2021-09-10 CL CL2021002373A patent/CL2021002373A1/es unknown
- 2021-09-12 IL IL286289A patent/IL286289A/en unknown
Also Published As
Publication number | Publication date |
---|---|
EA202192483A1 (ru) | 2021-12-24 |
CL2021002373A1 (es) | 2022-06-17 |
JPWO2020184691A1 (es) | 2020-09-17 |
EP3939659A4 (en) | 2022-12-21 |
IL286289A (en) | 2021-10-31 |
SG11202109982YA (en) | 2021-10-28 |
BR112021018084A8 (pt) | 2022-10-04 |
WO2020184691A1 (ja) | 2020-09-17 |
AU2020238177A1 (en) | 2021-11-04 |
CA3133204A1 (en) | 2020-09-17 |
BR112021018084A2 (es) | 2021-12-21 |
PE20220333A1 (es) | 2022-03-14 |
CN114126711A (zh) | 2022-03-01 |
US20220218664A1 (en) | 2022-07-14 |
KR20220009371A (ko) | 2022-01-24 |
EP3939659A1 (en) | 2022-01-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12020500673A1 (en) | Compounds | |
MY190137A (en) | Noxious organism control agent composition for agricultural and horticultural applications, and method for using said composition | |
MX2021006695A (es) | Moduladores de trex1. | |
MX2021014350A (es) | Compuestos de 1-oxo-isoindolin-5-carboxamida sustituida, composiciones de los mismos y metodos de tratamiento con los mismos. | |
SA520411524B1 (ar) | مركبات تنشيط القسيم العضلي ثنائي الأميد واستخداماتها | |
MX2020009530A (es) | Inhibidores de la o-glicoproteína-2-acetamido-2-desoxi-3-dglicopir anosidasa. | |
SG11201810704WA (en) | Sulfonamide compound or salt thereof | |
CR20220251A (es) | Nuevos derivados de metilquinazolinona | |
MX2021003686A (es) | Medicamento para el tratamiento de la tos cronica. | |
PH12020551486A1 (en) | Cyclopentane-based modulators of sting (stimulator of interferon genes) | |
PH12019500394A1 (en) | Bicyclic nitrogenated heterocyclic compound | |
MX2021004474A (es) | Compuestos que contienen deuterio. | |
MX2021011007A (es) | Farmaco y método para tratar o prevenir las complicaciones de la diabetes mediante el uso del mismo farmaco. | |
MX2024002885A (es) | Inhibidor de la proteasa 3clpro. | |
MX2024006991A (es) | Composiciones farmaceuticas inyectables y usos de las mismas. | |
MX2022006653A (es) | Compuestos para modular la actividad de fxr y usos de los mismos. | |
PH12019502078A1 (en) | Plant disease control agent | |
MX2021015188A (es) | Moduladores de nueva generacion del estimulador de genes de interferon (sting). | |
MX2022008665A (es) | Nuevo derivado de pirazol. | |
PH12016501906A1 (en) | Pyrimidine compound | |
MX2020006055A (es) | Composiciones farmaceuticas implantables de isoxazolina y usos de las mismas. | |
GEP20247590B (en) | Antibacterial quinolines | |
AU2017370226A1 (en) | Pharmaceutical composition containing insulin-like growth factor-2 and use thereof | |
MX2022008487A (es) | Degradadores de smarca2-vhl. | |
WO2018102256A8 (en) | Pyrrolidinone compounds |